tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Sugden PH Signalling pathways in cardiac myocyte hypertrophy. 2001 Ann. Med. pmid:11817656
Sun L et al. Cellular and molecular consequences of calcineurin A alpha gene deletion. 2007 Ann. N. Y. Acad. Sci. pmid:17872390
Shipston MJ et al. Glucocorticoid negative feedback in pituitary corticotropes. Pivotal role for calcineurin inhibition of adenylyl cyclase. 1994 Ann. N. Y. Acad. Sci. pmid:7529975
Iwanaga Y et al. Living donor islet transplantation, the alternative approach to overcome the obstacles limiting transplant. 2006 Ann. N. Y. Acad. Sci. pmid:17130575
Xu L et al. Potential for pharmacology of ryanodine receptor/calcium release channels. 1998 Ann. N. Y. Acad. Sci. pmid:10603942
Bers DM et al. Factors that control sarcoplasmic reticulum calcium release in intact ventricular myocytes. 1998 Ann. N. Y. Acad. Sci. pmid:10603944
Engelbrecht ME et al. The effect of immunosuppressants on human leukocyte NADPH oxidase. 1994 Ann. N. Y. Acad. Sci. pmid:7518204
Zuany-Amorim C et al. Modulation by rm interferon-gamma and CD4+ T-lymphocytes of allergic eosinophil accumulation in the mice peritoneal cavity. 1994 Ann. N. Y. Acad. Sci. pmid:7518212
Nagai H et al. The role of interleukin-5 (IL-5) in allergic airway hyperresponsiveness in mice. 1996 Ann. N. Y. Acad. Sci. pmid:8906215
Clipstone NA and Crabtree GR Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. 1993 Ann. N. Y. Acad. Sci. pmid:7509131
Takahara S Efficacy of FK506 in renal transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7509132
Thomson AW et al. Incidence of CD4+ IL-2R alpha+ and CD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (3 months) FK 506 therapy. 1993 Ann. N. Y. Acad. Sci. pmid:7509133
Lemster B et al. FK 506 inhibits cytokine gene and adhesion molecule expression in psoriatic skin lesions. 1993 Ann. N. Y. Acad. Sci. pmid:7509134
Tamura K et al. Inhibitory effect of FK 506 on autoimmune thyroid disease in the PVG rat. 1993 Ann. N. Y. Acad. Sci. pmid:7509135
Ochiai T et al. Combination of immunosuppressive drugs for organ transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7509136
Wiederrecht G et al. The mechanism of action of FK-506 and cyclosporin A. 1993 Ann. N. Y. Acad. Sci. pmid:7509138
Lee RK and Wurtman RJ Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors. 2000 Ann. N. Y. Acad. Sci. pmid:11193162
Christensen BG FK-506: its role in immunosuppression. 1993 Ann. N. Y. Acad. Sci. pmid:7689803
Kino T and Goto T Discovery of FK-506 and update. 1993 Ann. N. Y. Acad. Sci. pmid:7689804
Parsons WH et al. FK-506--a novel immunosuppressant. 1993 Ann. N. Y. Acad. Sci. pmid:7689805
Zenke G et al. Molecular mechanisms of immunosuppression by cyclosporins. 1993 Ann. N. Y. Acad. Sci. pmid:7689806
Clardy J Structural studies of complexed FK-506 binding protein. 1993 Ann. N. Y. Acad. Sci. pmid:7689808
Starzl TE et al. Allograft and xenograft acceptance under FK-506 and other immunosuppressant treatment. 1993 Ann. N. Y. Acad. Sci. pmid:7689809
Reem GH et al. FK-506 inhibits the IL-2-independent induction of the activation antigen CD 69. 1993 Ann. N. Y. Acad. Sci. pmid:7689811
Mollison KW et al. Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation. 1993 Ann. N. Y. Acad. Sci. pmid:7689812
Ponseti JM et al. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. 2008 Ann. N. Y. Acad. Sci. pmid:18096852
Paterson DL et al. Could a herpesvirus mimic tacrolimus-induced leukoencephalopathy? 1997 Ann. Neurol. pmid:9266742
Caprariello AV et al. Apoptosis of oligodendrocytes in the central nervous system results in rapid focal demyelination. 2012 Ann. Neurol. pmid:23034912
Keswani SC et al. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. 2003 Ann. Neurol. pmid:12509848
Dawson TM Immunosuppressants, immunophilins, and the nervous system. 1996 Ann. Neurol. pmid:8871573
Small SL et al. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506) 1996 Ann. Neurol. pmid:8871576
Roberts WK et al. A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease. 2015 Ann. Neurol. pmid:26224283
Wijdicks EF et al. FK506-induced neurotoxicity in liver transplantation. 1994 Ann. Neurol. pmid:7512320
Nelson M et al. Direct revascularization is superior for rat parathyroid allotransplantation with FK506. 2005 Ann. Otol. Rhinol. Laryngol. pmid:15825570
Gerster JC et al. Gout in liver transplant patients receiving tacrolimus. 2004 Ann. Rheum. Dis. pmid:15194597
Igarashi T et al. Central nervous system toxicity related to FK506 in patients with Behçet's disease. 1994 Ann. Rheum. Dis. pmid:7517134
Villaverde V et al. Leg bone pain syndrome in a kidney transplant patient treated with tacrolimus (FK506) 1999 Ann. Rheum. Dis. pmid:10577370
Duddridge M and Powell RJ Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. 1997 Ann. Rheum. Dis. pmid:9462174
Lightman S et al. Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet's disease with upregulation of circulating regulatory T cells and reduction of Th17. 2015 Ann. Rheum. Dis. pmid:25269831
Lampropoulos CE and D' Cruz DP Topical tacrolimus treatment in a patient with dermatomyositis. 2005 Ann. Rheum. Dis. pmid:16100347
Mok CC et al. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. 2016 Ann. Rheum. Dis. pmid:25550339
Lerut JP et al. Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation? Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study. 2014 Ann. Surg. pmid:25379858
Schlegel A et al. Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. 2014 Ann. Surg. pmid:25243553
Colombani PM et al. Liver transplantation in infants younger than 1 year of age. 1996 Ann. Surg. pmid:8645039
Todo S et al. Liver, kidney, and thoracic organ transplantation under FK 506. 1990 Ann. Surg. pmid:1697743
Stratta RJ et al. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. 1999 Ann. Surg. pmid:10235529
Shapiro R et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. 2003 Ann. Surg. pmid:14530723
Fealy MJ et al. Efficacy of rapamycin and FK 506 in prolonging rat hind limb allograft survival. 1994 Ann. Surg. pmid:7507657
Ozawa K et al. An appraisal of pediatric liver transplantation from living relatives. Initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. 1992 Ann. Surg. pmid:1280074
Vivarelli M et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. 2008 Ann. Surg. pmid:18948815
Abu-Elmagd K et al. Clinical intestinal transplantation: a decade of experience at a single center. 2001 Ann. Surg. pmid:11524593
Petruzzo P et al. Outcomes after bilateral hand allotransplantation: a risk/benefit ratio analysis. 2015 Ann. Surg. pmid:24646555
Todo S et al. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. 1994 Ann. Surg. pmid:7522431
Jain A et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. 1999 Ann. Surg. pmid:10493490
Lerut J et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. 2008 Ann. Surg. pmid:19092340
Schneeberger S et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. 2013 Ann. Surg. pmid:23001085
Bartlett ST et al. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. 1996 Ann. Surg. pmid:8857849
Todo S et al. Intestinal transplantation in composite visceral grafts or alone. 1992 Ann. Surg. pmid:1384443
Sho M et al. New insights into the interactions between T-cell costimulatory blockade and conventional immunosuppressive drugs. 2002 Ann. Surg. pmid:12409674
McCourtie AS et al. Synergistic protection in lung ischemia-reperfusion injury with calcineurin and thrombin inhibition. 2010 Ann. Thorac. Surg. pmid:20494024
Laubach VE Invited commentary. 2010 Ann. Thorac. Surg. pmid:20494025
Li S et al. Intrathymic inoculation of donor bone marrow induces long-term acceptance of lung allografts. 2003 Ann. Thorac. Surg. pmid:12537225
Sugita M et al. Pharmacologic modulation of alveolar liquid clearance in transplanted lungs by phentolamine and FK506. 2009 Ann. Thorac. Surg. pmid:19699927
Moffatt-Bruce S Invited commentary. 2009 Ann. Thorac. Surg. pmid:19699928
Thyagarajan GK et al. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. 1997 Ann. Thorac. Surg. pmid:9386723
Leshnower BG et al. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. 2008 Ann. Thorac. Surg. pmid:18805178
Chambers DJ Invited commentary. 2008 Ann. Thorac. Surg. pmid:18805179
Nathan M et al. Cyclosporin A but not FK-506 protects against dopamine-induced apoptosis in the stunned heart. 2005 Ann. Thorac. Surg. pmid:15854943
Hirai T et al. A short course of FK506 can induce limited donor-specific graft acceptance. 1994 Ann. Thorac. Surg. pmid:7520685
Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. 1992 Ann. Thorac. Surg. pmid:1379032
Oto T et al. Calcineurin inhibitor-related cholestasis complicating lung transplantation. 2010 Ann. Thorac. Surg. pmid:20417810
Groetzner J et al. Cardiac transplantation in pediatric patients: fifteen-year experience of a single center. 2005 Ann. Thorac. Surg. pmid:15620914
Inutsuka K et al. Reconstruction of trachea and carina with immediate or cryopreserved allografts in dogs. 1996 Ann. Thorac. Surg. pmid:8893587
Bolman RM Advantage--FK 506: reduced chronic rejection for lung transplant recipients. 1995 Ann. Thorac. Surg. pmid:7545888
Keenan RJ et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. 1995 Ann. Thorac. Surg. pmid:7545889
Foroncewicz B et al. A comparison between two tacrolimus-based immunosuppression regimens in renal transplant recipients: 7-year follow-up. 2013 Ann. Transplant. pmid:23896824
Arreola-Guerra JM et al. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. 2016 Ann. Transplant. pmid:26879833
Bäckman L and Persson CA An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients. 2014 Ann. Transplant. pmid:24637379
Girman P et al. The effect of bone marrow transplantation on survival of allogeneic pancreatic islets with short-term tacrolimus conditioning in rats. 2001 Ann. Transplant. pmid:11803619
Steinebrunner N et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. 2014 Ann. Transplant. pmid:24457606
Aguiar D et al. Real-World Multicenter Experience of Immunosuppression Minimization Among 661 Liver Transplant Recipients. 2017 Ann. Transplant. pmid:28461684
Tanaka T et al. Evaluation of immune function under conversion from Prograf to Advagraf in living donor liver transplantation. 2013 Ann. Transplant. pmid:23792533
Ueda K et al. Early corticosteroid withdrawal in the real world: a long-term analysis of kidney transplant recipients from the Mycophenolic Acid Observational Renal Transplant Registry. 2014 Ann. Transplant. pmid:24535029
Augusto JF et al. Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. 2013 Ann. Transplant. pmid:23872516
Zegarska J et al. Mycophenolic Acid Metabolites Acyl-Glucuronide and Glucoside Affect the Occurrence of Infectious Complications and Bone Marrow Dysfunction in Liver Transplant Recipients. 2015 Ann. Transplant. pmid:26313036
Bułanowski M et al. Influence of conversion from cyclosporine A to tacrolimus on insulin sensitivity assessed by euglicaemic hyperinsulinemic clamp technique in patients after kidney transplantation. 2012 Jul-Sep Ann. Transplant. pmid:23018257
Eguchi S et al. Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive interferon therapy after living donor liver transplantation. 2007 Ann. Transplant. pmid:18344932
Garaix F et al. Tacrolimus Granules for Oral Suspension as Post-Transplant Immunosuppression in Routine Medical Practice in France: The OPTIMOD Study. 2018 Ann. Transplant. pmid:30093607
Matia I et al. Immunosuppressive protocol with delayed use of low-dose tacrolimus after aortic transplantation suppresses donor-specific anti-MHC class I and class II antibody production in rats. 2014 Ann. Transplant. pmid:24815872
Gardiner KM et al. Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. 2016 Ann. Transplant. pmid:26729299
Fuchs U et al. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus. 2014 Ann. Transplant. pmid:24953848
Bösmüller C et al. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. 2012 Ann. Transplant. pmid:23274323
Olczak-Kowalczyk D et al. The status of dental and jaw bones in children and adolescents after kidney and liver transplantation. 2012 Ann. Transplant. pmid:23274327
Zakliczyński M et al. Clinical application of monitoring mycophenolic acid trough concentration in heart transplant recipients--single center's experience. 2005 Ann. Transplant. pmid:16218032
Mahalati K and Kahan BD Pharmacological surrogates of allograft outcome. 2000 Ann. Transplant. pmid:11217202
Ruangkanchanasetr P et al. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients. 2016 Ann. Transplant. pmid:27980321
Kishida N et al. Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. 2016 Ann. Transplant. pmid:27956735
Duvoux C et al. Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. 2015 Ann. Transplant. pmid:25588713
Albano L et al. Dosing of Enteric-Coated Mycophenolate Sodium Under Routine Conditions: An Observational, Multicenter Study in Kidney Transplantation. 2016 Ann. Transplant. pmid:27122116
Wyzgał J et al. Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors. 2007 Ann. Transplant. pmid:18173063